Authors: Sessa, C Wanders, J Roelvink, M Dombernowsky, P Nielsen, D Morant, R Drings, P Wissel, P Hanauske, AR

Citation: C. Sessa et al., Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG), ANN ONCOL, 11(2), 2000, pp. 207-210

Authors: Greenberg, HE Wissel, P Barrett, J Barchowsky, A Gould, R Farrell, D Panebianco, D Hand, E Gillen, L Goldberg, MR Bjornsson, TD

Citation: He. Greenberg et al., Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist,in healthy volunteers, J CLIN PHAR, 40(5), 2000, pp. 496-507

Authors: Stevenson, JP DeMaria, D Sludden, J Kaye, SB Paz-Ares, L Grochow, LB McDonald, A Selinger, K Wissel, P O'Dwyer, PJ Twelves, C

Citation: Jp. Stevenson et al., Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion, ANN ONCOL, 10(3), 1999, pp. 339-344

Authors: Parr, AF Sandefer, EP Wissel, P McCartney, M McClain, C Ryo, UY Digenis, GA

Citation: Af. Parr et al., Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and beagle dog, PHARM RES, 16(2), 1999, pp. 266-271